Ambience Healthcare, known for its comprehensive AI operating system for healthcare organizations, has successfully raised $70 million in a Series B funding round. This significant investment was co-led by Kleiner Perkins and the OpenAI Startup Fund, with contributions from existing investors like Andreessen Horowitz and Optum Ventures. The funding will be used to scale Ambience’s AI operating system, which is already making strides in the healthcare sector. The company’s AI operating system offers a suite of applications designed to alleviate clinician burnout, enhance system efficiency, and enable high-quality care. This includes AutoScribe, a real-time AI medical scribe; AutoCDI, a point-of-care…
Author: Abhay Panchal
The study, led by Hideaki Bando from National Cancer Center Hospital East, Chiba, Japan, was presented at the ASCO Gastrointestinal Cancers Symposium 2024 and published in the Journal of Clinical Oncology. The research was sponsored by the ARCADE Foundation, and the authors did not disclose any financial relationships. Key Findings: Significant Prognostic Factors Identified: Implications for Clinical Trials: Study Limitations and Future Research:
Dr. Dana Lukin, MD, AGAF, from Weill Cornell Medical College, praised the method for its potential in confirming IBD diagnoses and distinguishing IBD from non-IBD cases. However, he also highlighted the need to determine if cfDNA can differentiate between IBD and other conditions like colorectal cancer or infections that produce similar microbial signatures. Key Points: Future Directions: Considerations and Potential Applications:
Gastro Health has finalized a partnership with Gastroenterology and Nutrition Specialists in Orlando, Fla.Gastroenterology and Nutrition Specialists has one gastroenterologist, Asif Mohiuddin, MD, according to a Feb. 2 email shared with Becker’s from Gastro Health.Gastro Health has a footprint in Florida, Alabama, Washington, Virginia, Ohio, Maryland and Massachusetts. The company supports more than 400 physicians and has 150 locations.
The study evaluated the effectiveness of a treatment regimen combining pembrolizumab (an immune checkpoint inhibitor) with chemotherapy in patients with advanced gastric cancers. Key Findings: Study Details: Results: Implications:
The study involved 9,631 adults aged 35–65 years and analyzed various factors like demographic characteristics, behavioral habits, nutritional intake, physical activity, anthropometric indices, and GERD data. Key Findings: Conclusions:The study concludes that lifestyle and behavioral habits significantly influence the risk of developing GERD. Modifying these factors, such as reducing smoking and alcohol consumption, increasing physical activity, and adjusting dietary habits, can help prevent GERD. Additionally, addressing depression and managing obesity are important in reducing GERD risk.
Dive deep with Dr. Austin Lee Chiang, Chief Medical Officer at Medtronic Endoscopy, as he shares his journey and insights on the intersection of healthcare, social media, and technology. This interview is a must-watch for anyone interested in the evolving landscape of gastroenterology, digital health, and the power of social media in medicine. Highlights: Austin, with his unique blend of medical expertise and social media influence, brings a fresh and impactful perspective to the field of gastroenterology. His insights provide valuable lessons on the importance of embracing technology and social media to advance healthcare. Plus he has a cool new…
Inflammatory bowel disease (IBD) impacts 1.6 million people in the U.S. — and a new artificial intelligence-generated drug could help alleviate symptoms. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed IBD drug — ISM5411 — has entered Phase I clinical trials. This is Insilico’s fifth AI-designed drug to enter the pipeline. If approved, it would be the first medication to treat IBD by blocking prolyl hydroxylase domain (PHD), a protein that regulates the body’s gut barrier protection genes, according to Alex Zhavoronkov, PhD, founder and CEO of…
The Board of Directors of Satisfai Health Inc., a Canada-based leading medical solutions provider specializing in Artificial Intelligence (AI) applications in Gastroenterology, GI Endoscopy, and Intestinal Ultrasound, today announced that Ms. Solveig Johannessen, the company’s former Chief Operating Officer, is appointed to the Chief Executive Officer position. Accordingly, Dr. Michael Byrne, the company’s founder, will move up to become Executive Chairman and will also serve as Chief Medical Officer. The board of Satisfai Health expressed its deep appreciation to Dr. Byrne for his leadership as CEO since the company’s founding in 2015. Ms. Johannessen is an accomplished leader with over…
Medicare Advantage (MA) payments are set to decrease yet again in 2025 as the feds phase in significant changes to risk adjustment. As those overhauls begin to take effect, benchmark payments are set to decline by about 0.2% on average, according to the latest advance notice released by the Centers for Medicare & Medicaid Services (CMS). Despite this, the feds said Wednesday that payments to MA plans are expected to increase by 3.7% in 2025, a $16 billion increase over 2024. The payment rate announced today could change by the time the final rate announcement is published, no later than…